Group 1 - BRT Apartments Corp. has experienced a decline of approximately 45% in its share value since August 2022, primarily due to anticipated higher refinancing rates and an oversupply in the Sun Belt markets [2] Group 2 - The Insiders Forum, led by Chief Investment Strategist Bret Jensen, focuses on small and mid-cap stocks that are attractively valued and have seen significant insider purchases [2]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Clipper Realty Inc. held its Q3 2025 earnings call, discussing financial performance and future outlook [2][5]. Financial Performance - The call included discussions on non-GAAP financial measures such as adjusted funds from operations (AFFO), adjusted EBITDA, and net operating income (NOI) [4]. Management Participation - Key management figures participating in the call included David Bistricer (Co-Chairman and CEO), J.J. Bistricer (COO), and Larry Kreider (CFO) [2][5].

Core Insights - RenovoRx, Inc. reported a quarterly loss of $0.08 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.10 per share a year ago [1] - The company generated revenues of $0.27 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 35.12%, while revenues were zero a year ago [2] - RenovoRx shares have declined approximately 22.5% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Company Performance - The earnings outlook for RenovoRx is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.08 on revenues of $0.48 million, and -$0.31 on revenues of $1.51 million for the current fiscal year [7] - The company has surpassed consensus EPS estimates only once in the last four quarters [1] Industry Context - The Medical - Biomedical and Genetics industry, to which RenovoRx belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact RenovoRx's stock performance [5]

Group 1 - Rekor Systems, Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.05, and improved from a loss of $0.14 per share a year ago, representing an earnings surprise of +40.00% [1] - The company posted revenues of $14.19 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.39%, compared to year-ago revenues of $10.55 million [2] - The stock has gained approximately 41% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] Group 2 - The earnings outlook for Rekor Systems is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Rekor Systems was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $14.71 million, and -$0.27 on revenues of $49.14 million for the current fiscal year [7] Group 3 - The Zacks Industry Rank places the Internet - Software sector in the top 24% of over 250 Zacks industries, suggesting that stocks in the top 50% of Zacks-ranked industries outperform those in the bottom 50% by more than 2 to 1 [8]

Core Insights - The Oncology Institute, Inc. reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.12, but an improvement from a loss of $0.18 per share a year ago [1] - The company achieved revenues of $136.56 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 11.71% and showing a significant increase from $99.9 million in the same quarter last year [2] - The stock has increased approximately 1010% year-to-date, significantly outperforming the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, The Oncology Institute has not surpassed consensus EPS estimates, indicating challenges in meeting earnings expectations [2] - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $127 million, and for the current fiscal year, it is -$0.55 on revenues of $473.45 million [7] Market Outlook - The company's earnings outlook and management's commentary on the earnings call will be crucial for understanding future stock movements [3][4] - The Zacks Rank for The Oncology Institute is currently 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] - The Medical Services industry, to which The Oncology Institute belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, which may impact the stock's performance [8]

Core Viewpoint - Disney's shares fell nearly 8%, marking its worst day since April, despite reporting better-than-expected earnings but missing revenue targets [1] Financial Performance - Disney's TV networks and movie business negatively impacted results, and the company is currently in a carriage dispute with YouTube TV [1] - The company reported an increase of 11 million subscribers for Disney Plus, but this growth is largely attributed to wholesale subscriptions under a charter deal [12] Streaming and Future Outlook - There were high expectations for acceleration in the streaming segment, which is considered the future of the company, but no clear catalyst was identified [3][4] - CEO Bob Iger discussed plans for Disney Plus to evolve into a "super app" that integrates various Disney offerings, but this did not seem to excite investors [5] - The integration of Hulu and ESPN into a cohesive streaming strategy is seen as essential for future growth, with 80% of ESPN subscribers being part of a Disney Hulu bundle [6] Market Position and Competition - Disney is noted for having a strong presence across various demographics, including children, families, and sports, but it needs to demonstrate that this will drive growth [7] - The company has shown that its streaming growth is outpacing the decline in traditional media, with the majority of engagement and revenue now coming from streaming [11] Investor Sentiment - The market reaction to Disney's earnings was viewed as an overreaction, with some analysts suggesting that the stock has been priced for a prolonged period of stagnation [8][10] - Despite challenges, Disney is in a better financial position now, including a $7 billion share buyback plan, indicating recovery from previous difficulties [9]

Economic uncertainty and financial market volatility are expected to continue underpinning demand for the precious metal. Brendon Thorne / Bloomberg / Getty Images Close KEY TAKEAWAYS The price of gold surged in anticipation of the federal government shutdown, but now that it's over, the rally won't necessarily end. Ongoing robust investment demand amid continued economic uncertainty could keep driving gold higher, analysts say. Gold has hit a series of record highs this year, with the spot price surging as ...

Core Insights - Eisai Co., Ltd. and Biogen Inc. announced the approval of LEQEMBI® (lecanemab) for once every four weeks intravenous maintenance dosing in the UK, following its earlier approval for treating mild cognitive impairment and mild dementia due to Alzheimer's disease [1][2]. Group 1: Product Approval and Usage - LEQEMBI was initially approved in August 2024 for treating mild cognitive impairment and mild dementia in adult patients who are either apolipoprotein E ε4 heterozygotes or non-carriers [2]. - The new maintenance dosing regimen allows patients to transition from an 18-month treatment of 10 mg/kg every two weeks to 10 mg/kg every four weeks, or to continue the bi-weekly regimen [2]. Group 2: Alzheimer's Disease Context - Alzheimer's disease (AD) is characterized by amyloid-beta plaques and tau protein tangles in the brain, leading to neurodegeneration [3]. - LEQEMBI targets both amyloid plaques and protofibrils, which are believed to contribute to cognitive decline, making ongoing maintenance treatment crucial for slowing AD progression [3][5]. Group 3: Market and Demographics - In the UK, approximately 982,000 individuals are living with dementia, with AD being the cause in 60-70% of these cases, and these numbers are expected to rise with an aging population [4]. Group 4: Development and Collaboration - Eisai leads the global development and regulatory submissions for lecanemab, with both Eisai and Biogen co-commercializing and promoting the product [4][10]. - Lecanemab has been approved in 51 countries and is under regulatory review in 9 additional countries, indicating a broad international interest and potential market [7].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...